“This is a fair price, considering how much it costs the health care system to have a severe COVID-19 illness.
For us, the question is not about maximizing profits, ”Bansel said in an interview with Welt am Sonntag.
He noted that the price for the vaccine will vary depending on the volume of supplies.
Moderna said it plans to produce 20 million doses of the vaccine by the end of the year, with a “small portion” also available in Europe this year.
Earlier, RDIF evaluated the results of trials of the Moderna vaccine against coronavirus.